Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood

Sunil M. Kurian, Raymond Heilman, Tony S. Mondala, Aleksey Nakorchevsky, Johannes A. Hewel, Daniel Campbell, Elizabeth H. Robison, Lin Wang, Wen Lin, Lillian Gaber, Kim Solez, Hamid Shidban, Robert Mendez, Randolph L. Schaffer, Jonathan S. Fischer, Stuart M. Flechner, Steve R. Head, Steve Horvath, John R. Yates, Christopher L. MarshDaniel R. Salomon

Research output: Contribution to journalArticle

61 Scopus citations

Abstract

Background: Despite significant improvements in life expectancy of kidney transplant patients due to advances in surgery and immunosuppression, Chronic Allograft Nephropathy (CAN) remains a daunting problem. A complex network of cellular mechanisms in both graft and peripheral immune compartments complicates the non-invasive diagnosis of CAN, which still requires biopsy histology. This is compounded by non-immunological factors contributing to graft injury. There is a pressing need to identify and validate minimally invasive biomarkers for CAN to serve as early predictors of graft loss and as metrics for managing long-term immunosuppression. Methods: We used DNA microarrays, tandem mass spectroscopy proteomics and bioinformatics to identify genomic and proteomic markers of mild and moderate/severe CAN in peripheral blood of two distinct cohorts (n = 77 total) of kidney transplant patients with biopsy-documented histology. Findings: Gene expression profiles reveal over 2400 genes for mild CAN, and over 700 for moderate/severe CAN. A consensus analysis reveals 393 (mild) and 63 (moderate/severe) final candidates as CAN markers with predictive accuracy of 80% (mild) and 92% (moderate/severe). Proteomic profiles show over 500 candidates each, for both stages of CAN including 302 proteins unique to mild and 509 unique to moderate/severe CAN. Conclusions: This study identifies several unique signatures of transcript and protein biomarkers with high predictive accuracies for mild and moderate/severe CAN, the most common cause of late allograft failure. These biomarkers are the necessary first step to a proteogenomic classification of CAN based on peripheral blood profiling and will be the targets of a prospective clinical validation study.

Original languageEnglish (US)
Article numbere6212
JournalPloS one
Volume4
Issue number7
DOIs
StatePublished - Jul 10 2009

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood'. Together they form a unique fingerprint.

  • Cite this

    Kurian, S. M., Heilman, R., Mondala, T. S., Nakorchevsky, A., Hewel, J. A., Campbell, D., Robison, E. H., Wang, L., Lin, W., Gaber, L., Solez, K., Shidban, H., Mendez, R., Schaffer, R. L., Fischer, J. S., Flechner, S. M., Head, S. R., Horvath, S., Yates, J. R., ... Salomon, D. R. (2009). Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PloS one, 4(7), [e6212]. https://doi.org/10.1371/journal.pone.0006212